Please assess the completion status of the following clinical trial:

Trial Title: High-Dose Quinapril Versus Low-Dose Quinapril Plus Amlodipine in the Treatment of High-Risk Hypertensive Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with a documented history of hypertension defined as: SBP \> or = 140 mmHg or DBP \> or = 90 mmHg if hypertension untreated or patients currently treated for hypertension.~* Documented CAD or diabetes or impaired glucose tolerance~* Sinus rhythm~Principal Exclusion Criteria:~* Previous intolerance or allergic reaction to an ACE inhibitor, an ARB or dihydropyridine calcium channel blocker~* History of angioedema or cough related to previous ACE inhibitor use.~* Systolic blood pressure \> 180 mmHg or diastolic blood pressure \> 110 mmHg in untreated patients~* Systolic blood pressure \> 160 mmHg or diastolic blood pressure \> 100 mmHg in patients currently treated by an ACE inhibitor or an ARB~* Creatinine clearance \< 30 ml/min~* Significant liver dysfunction~* Current serum potassium \> or = 5 mmol/L or a history of marked ACE inhibitor or ARB induced hyperkalemia resulting in either a serum potassium \> or = 5.5 mmol/L or a life-threatening adverse event.~* History of HF or known LVEF \< or = 45%~* Bilateral renal artery stenosis (or unilateral if only one kidney)~* Unstable angina, myocardial infarction or coronary revascularization within the last 3 months.~* Connective tissue disease or chronic inflammatory condition~* Active malignancy~* Active infection in the last 2 weeks~* Inability or any contraindication to perform an exercise test.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).